Department of Reproductive Medicine

Michael McHale

Michael McHale, M.D.

Associate Physician Diplomate

Moores UCSD Cancer Center
Division of Gynecologic Oncology
3855 Health Sciences Drive Mail Code: 0987
La Jolla, CA 92093-0987
Academic Office: (858) 822-6199
Clinic Appointments: (858) 822-6100
Laboratory: (858) 534-7778
Fax: (858) 822-6319


Education


Fellowship
Gynecologic Oncology
1996-200
University of California, Irvine
Orange, California

Residency
Obstetrics and Gynecology
1992-1996
National Naval Medical Center
Bethesda, Maryland

Medical School
Medical Doctor
1988-1992
UHS/The Chicago Medical School
N. Chicago, Illinois

Undergraduate
BS Biology
Minor: Chemistry
Summa Cum Laude
1984-1988
Stonehill College
Massachusetts

Medical Licensure

California
DEA

Board Certification

American Board of Obstetrics and Gynecology, 11/01
American Boards of Obstetrics and Gynecology, Subspecialty Gynecologic Oncology 4/03

Academic Appointments

11/2007- present

Associate Clinical Professor, UCSD

8/2001- 10/2007

Assistant Residency Program Director

8/2000- 10/2007

Director, Resident Academics

6/2001- present

Founder, Director of the Annual Donald Gallup Research Symposium

7/2001- 10/2007

Assistant Chairman, Institutional Review Board
Naval Medical Center San Diego

7/2000- 10/2007

Oncology Advisory Board
Naval Medical Center San Diego

7/2000- 10/2007

Division Director Gynecologic Oncology
Department of Obstetrics and Gynecology
Naval Medical Center, San Diego
San Diego, California

7/2000- 10/2007

Clinical Assistant Professor
Obstetrics and Gynecology
Uniformed Services University of the Heath Sciences

7/96 - 6/2000

Clinical Instructor
Department of Obstetrics and Gynecology
UCI Medical Center, Orange California

Non-Academic Appointments

8/00 – 1/02 Medicine for Humanity, Director of Missions to Mexico

5/89 - 7/89 Officer Indoctrination School, Newport, Rhode Island

Professional Activity

Awards and Honors

10/07- present Chairman, Navy Section, Armed Forces District, ACOG
10/06 Outstanding Poster, Pacific Coast Ob/Gyn Annual Meeting
6/05 CREOG National Faculty Award
10/04-10/07 Vice-Chairman, Navy Section of Fellows, Armed Forces District , ACOG
10/03- 10/04 Scientific Chairman, Armed Forces District Meeting, American College of
Obstetrics and Oncology
10/02 Resident Outstanding Paper Award, Senior Author, ACOG Armed Forces
District Meeting, Honolulu, Hawaii
10/95 - 10/96 Chairman, Navy Section of Junior Fellows, Armed Forces District, American College of Obstetricians and Gynecologists
10/95 Resident Outstanding Paper Award, Armed Forces District, American College of Obstetricians and Gynecologists, San Diego, California
10/94 - 95 Vice Chairman, Navy Section of Armed Forces District, American College of Obstetricians and Gynecologists
7/95 Resident Day Research Award
6/95 Golden speculum Award - Outstanding Resident Award
1992 UHS/CMS Dean's Award for Outstanding Service
1988 Naval Health Professional Scholarship
1988 Stonehill College Outstanding Service and Achievement Award
1988 Summa Cum Laude
1986 Lambda Epsilon Sigma (Stonehill Honor Society)
1986 Sigma Zeta (Biology Honor society)
1984-88 President, Class of 1988, four consecutive terms

Research Activity

Investigational Trials
Gynecologic Oncology Group: 126 series DTM 0804 ( Satraplatin )

Topotecan plus Cisplatin induction followed by Paclitaxel consolidation for the treatment of Stage III and IV epithelial ovarian cancer and primary peritoneal cancer with in vitro correlates of response. (Co-Investigator)

Gynecologic Oncology Group – Principle Investigator, Walter Reed Army Medical Center Affiliate

Invited Presentations

1. Speaker, Tamoxifen and the Gynecologic Patient. University of California, Irvine Medical Center, Department of Gynecology, 1997

2. Speaker, Controversies in the Management of Early Invasive Ovarian Cancer, Long Beach Memorial Hospital, Grand Rounds, 1999

3. Speaker, Tamoxifen and the Gynecologic Patient, Grand Rounds, Long Beach Memorial Hospital, Grand Rounds 1998

4. Speaker, Endometrial Cancer: Management and Controversies. Grand Rounds, University of California, Irvine Medical Center, Department of Obstetrics and Gynecology, Sept 1998.

5. Speaker, The Post Menopausal Mass: Observation Versus Definitive Management. University of California, Irvine Medical Center, Department of Obstetrics and Gynecology, Nov 1999.

6. Speaker, The Postmenopausal Mass: Observation Versus Definitive Management. Fountain Valley Regional Medical Center Lecture Series, Apr 2000.

7. Speaker, The Postmenopausal Cystic Mass. American College of Obstetricians and Gynecologists, Armed Forces District Meeting, Oct 2000

8. Speaker, Hormone Replacement Therapy: Myth and Non-Fiction. Women's Health Symposium, Naval Medical Center, San Diego, Dec 2000

9. Speaker, Gynecologic Cancer Screening. Women’s Health Symposium, Naval Medical Center, San Diego, December 2001

10. Speaker, Hormone Therapy: That was then, this is now. Women’s Health Symposium, Naval Medical Center, San Diego, December 2003

11. Course Director, Society of Gynecologic Oncology, 2004 Annual Clinical Meeting, San Diego, CA. Preoperative Assessment

12. Speaker, Cancer Screening: Who, How, Why. Women’s Health Symposium, Naval Medical Center, San Diego, December 2004.

13. Speaker, HPV: The Latest Update. Women’s Health Symposium, Naval Medical Center, San Diego, December 2005

14. Speaker, Genetic Testing: Who, Why, and What can be done. Women’s Health Symposium, Naval Medical Center, San Diego, December 2006.

15. Speaker, HPV: Current Strategies. Women’s Health Symposium, Naval Medical Center, San Diego, December 2007.

16. Speaker, Urologic Complications of Gynecologic Surgery. 55th Annual James C. Kimbrough Urological Seminar, San Diego, January 2008.

Publications

Book Chapters

1. McHale MT, Berman ML. Endometrial Cancer. Cancer Treatment, Fifth Edition. Charles M. Haskell. WB Saunders Company

2. Gynecologic Oncology, PROLOG 2006 edition, American College of Obstetrics and Gynecology

Journal Articles, Peer Reviewed

1. Hornung R, Major AL, McHale MT, Liaw LH, Sabiano LA, Tromberg BJ, Berns M,
Tadir Y. In vivo detection of metastatic ovarian cancer by means of 5-amino levulinic
acid-induced flourescence in a rat model. J of Am Ass of Gyn Lap 1998;5(2):141-148.

2. McHale MT, DiSaia PJ. Fertility-sparing treatment of patients with ovarian cancer.
Comp Ther 1999; 15(3):144-50.

3. Cloven NG, Re A, McHale MT, Burger RA, DiSaia PJ, Rose GS, Campbell KC, Fan H. Evaluation of d-methionine as a cytoprotectant in cisplatin treatment of an animal model for ovarian cancer. Anticancer Research 2000; 20 (6b): 4205-9.

4. Suriano K, McHale MT, McLaren C, DiSaia PJ, Long term follow up of estrogen replacement therapy in endometrial cancer patients. Obstet and Gynecol 2001;97:555-560.

5. Keefe KA, Schell MJ, Brewer C, McHale MT, Brewster W, Chapman J et al. A randomized, double blind , Phase III trial using oral beta-carotene supplementation for women with high grade cervical intraepithelial neoplasia. Cancer Epidemiol Biomarkers Prev, 2001; 10:1029-1035.McHale MT, Monk BJ, Keefe KA, Peng Y, Meyskens FL, Berman ML. Influence of serum and tissue micronutrient levels on the regression rate of CIN II and III. Cancer Epidemiol Biomarkers Prev 2001;10(10): 1029-1035.

6. McHale MT, Le T, Gu M, Rutgers J, Monk BJ. Fertility sparing treatment of microinvasive adenocarcinoma and adenocarcinoma in situ of the cervix. Obstet and Gynecol 2001;98:726-31.

7. Tewari DS, McHale MT, Kuo JV, Monk BJ, Burger Ra. Primary Invasive Vaginal Cancer in the Setting of Mayer-Rokitansky-Kuster Hauser Syndrome. Gynecol Oncol 2002;85(2):384-387.

8. McHale MT, Monk BJ, Keefe KA, Peng Y, Meyskens FL, Berman ML. Influence of serum and tissue micronutrient levels on the regression rate of CIN II and III.
J of Low Genital Tract Dis 2002; 6(4):220-224.

9. Kaplan KJ, Dainty LA, Dolinsky B, Rose GS, Carlson J, McHale M, Elkas JC. Prognosis and recurrence risk for patients with cervical squamo-intraepithelial lesions diagnosed with pregnancy. Cancer 2004;102(4):228-32.

10. You W, Dainty LA, Rose GS, Krivak T, McHale MT, Olsen CH, Elkas JC. Gynecologic malignancies in women aged less than 25 years. Obstet Gynecol 2005; 105(6):1405-9.

11. Hodgson W, Kaplan KJ, Rodriguez M, McHale MT, Rose GS, Elkas JC. The impact of converting to liquid-based cervical cytology in a military population. Gynecol Oncol 2005; 99(2):422-6.

12. Yamada S, Sweitzer B, McHale M, Preoperative assessment for gynecologic surgery.
Contemporary OB/GYN. 2005;50(2):50-57

13. Stany MP, Bidus MA, Reed EJ, Kaplan KJ, McHale MT, Rose GS, Elkas JC. The prevalence of HR-HPV DNA in ASC-US Pap smears: A military population study. Gynecol Oncol 2006;101(1):82-5.

14. McHale MT, Souther J, Steele J, Elkas JC, Monk B, and Harrison TA. The clinical
significance of atypical squamous cells, cannot exclude a high-grade lesion (ASC-H),
identified on cervical cytologic screening. J Lower Gen Trac Dis 2007; 11(2)86-90.

15. Milspaw J, Gable P, Quigley M, and McHale MT. Primitive Neuroectodermal Tumor of
Uterus. Gynecol Oncol 2007;106:419-422.

Selected Abstracts and Posters

1. Rose GS, Santin A, Re A, Granger G, DiSaia PG, McHale MT, Hiserodt J. IL-2 and the NuTu-19 epithelial ovarian carcinoma animal model. Poster Presentation, the 28th Annual Meeting of the Society of Gynecologic Oncologists (SGO), Phoenix AZ, Mar 1997.

2. McHale MT, Chen T, Re A, Gatanaga T, Granger M, Hiserodt J. Successful development of systemic immunity to a non-immunogenic glioma, D74, using tumor cells engineered to secrete rat interleukin 4. The American College of Obstetricians and Gynecologists, Armed Forces District Meeting, Orlando, FL, Oct 1998.

3. McHale MT, Monk BJ, Upsani S, Peng Y, Brewer CA, Keefe KA, Meyskens F, Berman ML. The influence of serum and tissue micronutrient levels on the regression rate of CIN II and III. The 28th Annual Meeting of the Western Association of Gynecologic Oncologists, British Columbia, Canada, Jun 1999.

4. McHale MT, Monk BJ, Upsani S, Peng Y, Brewer CA, Keefe KA, Meyskens F, Berman ML. The influence of serum and tissue micronutrient levels on the regression rate of CIN II and III. The Chao Family Comprehensive Cancer Center Symposium on Carcinogenesis and Cancer Prevention. Irvine CA, Jul 1999.

5. Gillete-Cloven NG, Re A, McHale MT, Rose GS, Campbell K, Burger RA, DiSaia PJ, Fan H. D-methionine allows for dose escalation of cisplatin in the treatment of an ovarian cancer model. The 29th Annual Meeting of the Western Association of Gynecologic Oncologists, Monterey CA, May 2000.

6. Chan JK, Monk BJ, Keefe KA, McHale MT. HPV infections, sexual risk factors and histologic grade are strong predictors for regression of high grade cervical dysplasia. The 29th Annual Meeting of the Western Association of Gynecologic Oncologists, Monterey

7. McHale MT, Le T, Gu M, Rutgers J, Monk BJ. Fertility sparing treatment of microinvasive adenocarcinoma and adenocarcinoma in situ of the cervix. The 29th Annual Meeting of the Western Association of Gynecologic Oncologists, Monterey CA, May 2000.

8. Soriano K, McHale MT, Re A, McLaren C, DiSaia PJ. Long term follow up of estrogen replacement therapy in endometrial cancer patients. The 31st Annual Meeting of the Society of Gynecologic Oncologists, San Diego CA, Feb 2000.

9. Keefe KA, MC, McHale MT, Brewer C, Chapman J, Rose GS, Lagerberg W, Wilczynski S, Schell M, Meyskens FL, Berman ML. The effects of beta-carotene on high grade CIN: a two year phase II trial. The 31st Annual Meeting of the Society of Gynecologic Oncologists, San Diego CA, Feb 2000.

10. Farrell M, Fuller-Eddins T, Kane E, Harrison T, McHale MT. The clinical significance of endocervical curettage in women with atypical squamous cells of undetermined significance. Armed forces District of the American College of Obstetrics and Gynecology, Oahu, Hawaii, October 2002.

11. Gaffney D, Kane E, Harrison T, McHale M. A Multimodal Approach for the Treatment of Stage IB2 Small Cell Carcinoma of the Cervix. Donald Gallop Research Symposium, San Diego CA., June 2003.

12. Fuller-Eddins T, Takahashi J, Steele J, Harrison T, McHale MT. The clinical significance of endocervical curettage in women with atypical squamous cells of undetermined and a positive HPV. Armed Forces District of the American College of Obstetrics and Gynecology, San Diego, CA, October 2004.

13. Souther J, Harrison T, Elkas J, McHale M. The effect of the route of delivery
on the regression of antepartum high grade cervical dysplasia in the
immediate postpartum evaluation. Armed forces District of the American College of Obstetrics and Gynecology, San Diego, CA, October 2004.

14. Alkhas A, Harrison T, McHale M. Loop excision for a case of Epithelioid Trophoblastic Tumor confined to the Cervix. Armed Forces District of the American College of Obstetrics and Gynecology, San Diego, CA, October 2004.

15. Fuller-Eddins T, Takahashi J, Steele J, Elkas JC, Harrison T, McHale MT. The clinical significance of endocervical curettage in women with atypical squamous cells of undetermined and a positive HPV. Society of Gynecologic Oncology Annual Meeting, Miami, Florida, March 2005.

16. Borja C and McHale MT. An aggressive variant of ovarian granulosa cell tumor
responsive to carboplatin and paclitaxel: a case report and review of the literature.
Donald Gallop Research Symposium, San Diego CA., June 2005.

17. Fuller-Eddins T, Takahashi J, Elkas J, Harrison TA, and McHale MT. Cumulative risk of cervical intraepithelial neoplasia (CIN) 2 or 3in patients with atypical squamous cells of undetermined significance and HPV+ after one year of follow-up. Donald Gallop Research Symposium, San Diego CA., June 2005.

18. Milspaw J, Gable P, and McHale MT. A primitive neuroectodermal tumor of the uterus. Donald Gallop Research Symposium, San Diego CA., June 2005.

19. Souther J, Steele J, Elkas JC, Monk B, Harrison TA, and McHale MT. The clinical significance of atypical squamous cells, cannot exclude a high-grade lesion (ASC-H), identified on cervical cytologic screening. Society of Gynecologic Oncology Annual Meeting, Palm Springs, CA, March 2006.

20. McHale MT, Fuller-Eddins T, Takahashi J, Elkas J, and Harrison TA. Cumulative risk of cervical intraepithelial neoplasia (CIN) 2 or 3in patients with atypical squamous cells of undetermined significance and HPV+ after one year of follow-up. Society of Gynecologic Oncology Annual Meeting, Palm Springs, CA, March 2006.

21. Takahashi J, Barbier H, Snitcher A, Harrison TA and McHale MT. Should reflex HPV testing be utilized for the cytologic diagnosis atypical squamous cells, can not exclude a high grade lesion? Donald Gallop Research Symposium, San Diego CA., June 2006.

22. Byrd K, Furlong DM, Harrison TA, and McHale MT. Single visit management of
high-grade squamous intraepithelial lesion with loop excision: Correlation with histologic findings, colposcopy and long-term follow-up. Donald Gallop Research Symposium, San Diego CA., June 2006.

23. Takahashi J, Barbier H, Snitcher A, Harrison TA and McHale MT. Should reflex HPV testing be utilized for the cytologic diagnosis atypical squamous cells, can not exclude a high grade lesion? Pacific Coast Obstetric and Gynecology Society Meeting, Sun Valley Idaho, September 2006.

Faculty